These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12911792)

  • 1. In vitro and in vivo allergenicity of recombinant Bet v 1 compared to the reactivity of natural birch pollen extract.
    Tresch S; Holzmann D; Baumann S; Blaser K; Wüthrich B; Crameri R; Schmid-Grendelmeier P
    Clin Exp Allergy; 2003 Aug; 33(8):1153-8. PubMed ID: 12911792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fagales pollen sensitization in a birch-free area: a respiratory cohort survey using Fagales pollen extracts and birch recombinant allergens (rBet v 1, rBet v 2, rBet v 4).
    Mari A; Wallner M; Ferreira F
    Clin Exp Allergy; 2003 Oct; 33(10):1419-28. PubMed ID: 14519150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System.
    Movérare R; Elfman L; Vesterinen E; Metso T; Haahtela T
    Allergy; 2002 May; 57(5):423-30. PubMed ID: 11972482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations.
    Niederberger V; Pauli G; Grönlund H; Fröschl R; Rumpold H; Kraft D; Valenta R; Spitzauer S
    J Allergy Clin Immunol; 1998 Oct; 102(4 Pt 1):579-91. PubMed ID: 9802365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant Bet v 1, the major birch pollen allergen, induces hypersensitivity reactions equal to those induced by natural Bet v 1 in the airways of patients allergic to tree pollen.
    Godnic-Cvar J; Susani M; Breiteneder H; Berger A; Havelec L; Waldhör T; Hirschwehr R; Valenta R; Scheiner O; Rüdiger H; Kraft D; Ebner C
    J Allergy Clin Immunol; 1997 Mar; 99(3):354-9. PubMed ID: 9058691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season.
    van Hage-Hamsten M; Kronqvist M; Zetterström O; Johansson E; Niederberger V; Vrtala S; Grönlund H; Grönneberg R; Valenta R
    J Allergy Clin Immunol; 1999 Nov; 104(5):969-77. PubMed ID: 10550741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced in vivo allergenicity of Bet v 1d isoform, a natural component of birch pollen.
    Arquint O; Helbling A; Crameri R; Ferreira F; Breitenbach M; Pichler WJ
    J Allergy Clin Immunol; 1999 Dec; 104(6):1239-43. PubMed ID: 10589007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different IgE reactivity profiles in birch pollen-sensitive patients from six European populations revealed by recombinant allergens: an imprint of local sensitization.
    Movérare R; Westritschnig K; Svensson M; Hayek B; Bende M; Pauli G; Sorva R; Haahtela T; Valenta R; Elfman L
    Int Arch Allergy Immunol; 2002 Aug; 128(4):325-35. PubMed ID: 12218371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2: diagnostic value for birch pollen and associated allergies.
    Pauli G; Oster JP; Deviller P; Heiss S; Bessot JC; Susani M; Ferreira F; Kraft D; Valenta R
    J Allergy Clin Immunol; 1996 May; 97(5):1100-9. PubMed ID: 8626988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality and potency profile of eight recombinant isoallergens, largely mimicking total Bet v 1-specific IgE binding of birch pollen.
    Seutter von Loetzen C; Reuter A; Spiric J; Schulenborg T; Bellinghausen I; Völker E; Vogel L; Rösch P; Schiller D
    Clin Exp Allergy; 2019 May; 49(5):712-723. PubMed ID: 30706562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe oral allergy syndrome and anaphylactic reactions caused by a Bet v 1- related PR-10 protein in soybean, SAM22.
    Kleine-Tebbe J; Vogel L; Crowell DN; Haustein UF; Vieths S
    J Allergy Clin Immunol; 2002 Nov; 110(5):797-804. PubMed ID: 12417891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population.
    Pauli G; Purohit A; Oster JP; De Blay F; Vrtala S; Niederberger V; Kraft D; Valenta R
    Clin Exp Allergy; 2000 Aug; 30(8):1076-84. PubMed ID: 10931114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments.
    Campana R; Moritz K; Marth K; Neubauer A; Huber H; Henning R; Blatt K; Hoermann G; Brodie TM; Kaider A; Valent P; Sallusto F; Wöhrl S; Valenta R
    J Allergy Clin Immunol; 2016 Feb; 137(2):601-609.e8. PubMed ID: 26518092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical relevance of birch pollen profilin cross-reactivity in sensitized patients.
    Wölbing F; Kunz J; Kempf WE; Grimmel C; Fischer J; Biedermann T
    Allergy; 2017 Apr; 72(4):562-569. PubMed ID: 27588729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of specific IgE antibodies in sera of Japanese birch-allergic patients using recombinant allergens Bet v 1, Bet v 2 and Bet v 4.
    Shirasaki H; Yamamoto T; Koyanagi Y; Watanabe N; Himi T
    Allergol Int; 2008 Mar; 57(1):93-6. PubMed ID: 18209509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of IgE antibodies in mice and rhesus monkeys with recombinant birch pollen allergens: different allergenicity of Bet v 1 and Bet v 2.
    Vrtala S; Mayer P; Ferreira F; Susani M; Sehon AH; Kraft D; Valenta R
    J Allergy Clin Immunol; 1996 Nov; 98(5 Pt 1):913-21. PubMed ID: 8939154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects.
    Winther L; Malling HJ; Mosbech H
    Allergy; 2000 Sep; 55(9):827-35. PubMed ID: 11003446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between IgE antibodies to recombinant allergens rBet v 1 and rBet v 2 and food causing oral allergy syndrome in cases of birch-pollen allergy].
    Yamamoto T; Asakura K; Shirasaki H; Himi T
    Nihon Jibiinkoka Gakkai Kaiho; 2010 Aug; 113(8):661-9. PubMed ID: 20845708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.
    Pauli G; Larsen TH; Rak S; Horak F; Pastorello E; Valenta R; Purohit A; Arvidsson M; Kavina A; Schroeder JW; Mothes N; Spitzauer S; Montagut A; Galvain S; Melac M; André C; Poulsen LK; Malling HJ
    J Allergy Clin Immunol; 2008 Nov; 122(5):951-60. PubMed ID: 19000581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis.
    van Hage-Hamsten M; Johansson E; Roquet A; Peterson C; Andersson M; Greiff L; Vrtala S; Valenta R; Grönneberg R
    Clin Exp Allergy; 2002 Oct; 32(10):1448-53. PubMed ID: 12372124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.